Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
FDA-approved medications are preferred when clinically appropriate
Treatments like SGLT2i and GLP-1 RA are recommended as part of a comprehensive approach to reduce cardiorenal outcome risk, often in addition to established treatments like RAASi in patients with type 2 diabetes
The benefits in ASCVD risk reduction with GLP-1RA are evidenced by 14% risk reduction in cardiovascular mortality with an NNTB of 207 to prevent one event, 13% MACE reduction with an NNT of 67 to prevent one event and 12% risk reduction in stroke with an NNT of 335 to prevent one event, along with their favourable safety profile of 6% increased overall adverse events
Factors like stress, poor gut health, or certain medications can reduce absorption even further
Some require insurance
US$ 22.93
)
US$ 24.51
US$ 27.87
US$ 24.63
